Novartis to manufacture CureVac’s Covid-19 vaccine candidate CVnCoV
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Mar 21
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
03 Feb 21
WuXi STA will acquire the operations and assets of Couvet site, including the plant and equipment, along with…
28 Dec 20
Covaxx, is currently conducting phase 1 clinical trial for the vaccine candidate
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Dec 20
By 31 July 2021, the US government is expected to get 200 million doses of the BNT162b2 Covid-19…
07 Dec 20
Sinovac will use the funding to further develop and expand the manufacturing capacity of its vaccine candidate CoronaVac
01 Oct 20
VLP Therapeutics’ Covid-19 vaccine is said to be a self-amplifying RNA vaccine that leverages lipid nanoparticle formulation, a…
06 Aug 20
The US supply of Janssen’s investigational Covid-19 vaccine is subject to the regulatory approval or receipt of Emergency…
05 Aug 20
The UK government and Valneva announced a joint investment to expand the Livingston facility for enhanced vaccine manufacturing…
22 May 20
Samsung Biologics is expected to provide GSK with additional capacity for large-scale manufacture of biopharmaceutical products
24 Mar 20
Thermo Fisher has completed $50m expansion at the St. Louis site to increase the production capacity for biological…